Intergroupe Francophone De Cancerologie Thoracique
Clinical trials sponsored by Intergroupe Francophone De Cancerologie Thoracique, explained in plain language.
-
New hope for Tough-to-Treat lung cancer: trial tests powerful drug combo
Disease control Not yet recruitingThis study is testing whether adding a new immunotherapy drug (fianlimab) to an existing treatment (cemiplimab plus standard chemotherapy) is safe and can better control advanced pleural mesothelioma, a cancer often linked to asbestos exposure. It will enroll 126 adults who have …
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for lung cancer patients with scarred lungs
Disease control Not yet recruitingThis study aims to find safer and more effective treatments for people with advanced lung cancer who also have a separate lung-scarring disease (ILD). It will test a standard chemotherapy combination for patients receiving their first treatment, and test an immunotherapy drug for…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC